Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Randomised trials of rituximab maintenance (MR) for patients with follicular lymphoma support improved progression-free survival (PFS), but the effect on overall survival has been inconclusive. To evaluate the effect of MR on overall survival according to patient and disease characteristics, and to explore certain adverse events, we performed an individual patient data (IPD) meta-analysis.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur. J. Cancer

Title: European journal of cancer (Oxford, England : 1990)

Publisher: Elsevier BV

ISSN (Electronic): 1879-0852

ISSN (Print): 0959-8049

Publication date (Electronic): May 2017

Volume: 76

Affiliations

[1 ] Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. Electronic address: vidallit@yahoo.com.

[2 ] Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Internal Medicine A, Rabin Medical Center, Petah Tikva, Israel.

[3 ] Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Benite, Université Claude Bernard Lyon-1, Lyon, France.

[4 ] Biostatistics Department, LYSARC, Pierre-Benite, France.

[5 ] Sheba Medical Center, Gertner Institute for Epidemiology and Health Policy Research, Tel Hashomer, Israel.

[6 ] EORTC Lymphoma Group/HOVON, Academic Medical Center, Amsterdam, The Netherlands.

[7 ] EORTC, Brussels, Belgium.

[8 ] Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Swiss Group for Clinical Cancer Research, Bern, Switzerland.

[9 ] Department of Haematology, St. George's University of London, London, UK.

[10 ] Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.

[11 ] EBMT Lymphoma Working Party, Paris, France.

[12 ] Città della Salute e della Scienza Hospital and University, on behalf of FIL, Turin, Italy.

[13 ] CEDOC, Instituto Português de Oncologia de Lisboa Francisco Gentil EPE Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal.

[14 ] University-Hospital Città della Salute e della Scienza, Torino, Italy.

[15 ] Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MS, USA.

[16 ] Division of Hematology, Mayo Clinic, Rochester, MN, USA.

[17 ] Assuta Medical Center, Tel Aviv, Israel.

Article

Publisher Item ID: S0959-8049(17)30082-5

DOI: 10.1016/j.ejca.2017.01.021

PubMed ID: 28336303

SO-VID: d7b84aaa-f117-4e01-9100-e84a0ed5c3ee

History

Keywords: Follicular lymphoma,Maintenance,Meta-analysis,Rituximab

Data availability:

Keywords: Follicular lymphoma, Maintenance, Meta-analysis, Rituximab

Comments

Comment on this article

scite_

Cited by 23

See all cited by